This article was originally posted on Nutritional Outlook. To read the original piece, click here. According to the U.S. Census Bureau, Americans are living longer than
Information about the COVID-19 virus (SARS-CoV-2) is constantly changing. This leaves essential business and healthcare facilities scrambling to find ways to ensure their employees, customers’
Investment will be used to further develop the Company’s Precisome platform for functional analysis New investment led by Oregon Venture Fund Dr Stephen Turner
Dr. Adrian Wolstenholme graduated from the University of London with a BSc in Biochemistry and has since spent almost 43 years working in the lab.
In preparation for the Precision Medicine World Conference on January 20-23rd, 2019, PMWC took a moment to ask us some questions about the new and
Thursday November 15th, 2018 – NemaMetrix wins the “Job Creation” Award at the RG Media Company’s inaugural Innovation and Talent Celebration. The event was organized
Performing sequence analysis on a patient with a suspected genetic disease is becoming a standard of care. However, when a genetic variation is identified as
My academic research at the University of Oregon concerns the neuronal basis of behavior in one of the smallest brains known to science,
‘Those of us who have studied invertebrate model organisms throughout our careers have been nervous that NIH study sections will shut the door on our funding in favor of funding studies in mammals. But my last grant application to the NIH proposing experiments in C. elegans got a perfect score! ‘
NemaMetrix Inc. is the winner of the first “Most Innovative” health startup at Demo Day organized by CBInsights.
The latest issue of Drug Discovery News (DDNews) features a special report on Animal Models of Disease, highlighting the NemaMetrix/Knudra merger and the value of C. elegans as a model organism for disease research.
Dr. Andy Golden at NIH discusses his work on identifying regulators and interactors of conserved genes in C. elegans that, when mutated, can cause human disease and opportunities to use C. elegans as a model in clinical and translational research.
NemaMetrix, a company developing nematode-based drug development and screening technologies, announced the launch of its first series of RediStain™ fluorescent kits for improved visualization of C. elegans’ structure and function in phenotyping studies. These kits expand the toolkit of C. elegans research to include the ability to perform structural and functional assays that are standard in cell biology.
We discovered that in the absence of cholesterol, NPC mutants display a lower pharyngeal pumping frequency and a longer duration between pumps than control N2 animals. This is the progress we made in our collaborative research project with Perlara and investigation into the lysosomal disorder, Niemann-Pick Type C (NPC).
NemaMetrix Inc. was selected as the only company representing the state of Oregon by the Science Coalition in its latest Sparking Economic Growth reports released Apr 25, 2017.
Nemametrix Inc., a life sciences startup that created the innovative ScreenChip System for drug screening, mutant phenotyping, and toxicological assessment, has entered into a marketing partnership with Knudra Transgenics, a genome engineering company specializing in custom built transgenic model organisms for research and drug discovery.
The NemaMetrix ScreenChip platform technology was recognized by the White House as one of the breakthrough life science research technologies. CEO Matt Beaudet spoke with Dr. Robbie Barbero of the US White House Office of Science and Technology Policy, who created a post on the White House website about the promise of new research technologies.
NemaMetrix announces being awarded $188,000 for a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Health. The funds will be used to support fundamental proof of concept research, with an eye towards near-term commercialization, of a microfluidic screening device for health-span extending drugs.